Shuttle Pharmaceuticals (SHPH) said late Thursday it filed a provisional US patent for prostate-specific membrane antigen ligand conjugates to treat prostrate cancer.
The patent, "PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy," could advance diagnostic and therapeutic programs for patients with metastatic castration-resistant prostate cancer, the company said.
PSMA is expressed on the surface of cancer cells, and ligands targeting the antigen are smaller and present potential advantages for more efficient drug delivery, according to a company statement.
Shares are up nearly 10% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.